HK Stock Market Move | DUALITYBIO-B(09606) rose more than 6% in the early trading session, with its core product DB-1311 showing significant efficacy. The global Phase III clinical trial has been launched as scheduled.

DUALITYBIO-B(09606) rose more than 6% in the early session, rising 5.91% as of press time to HK$308.4, with a turnover of HK$61.318 million. On the news front, Ying'en Life Sciences announced in a poster format at the 2026 ASCO GU the latest clinical data of DB-1311/BNT324 developed in collaboration with BioNTech in mCRPC patients, which was derived from a global multicenter Phase I/II clinical trial. With a mrPFS of 11.3 months, it refreshed the record of B7H3ADC in this field. Based on these data, the company and BioNTech have already launched a global Phase III clinical trial as scheduled, actively promoting global marketing. China Securities Co., Ltd. released a research report stating that looking forward to 2026, the company's DB-1303 is expected to submit a global marketing application to the US FDA for endometrial cancer, submit a China marketing application to CDE for HER2+ breast cancer after-line indications, and update global Phase III clinical data for HER2 low-expressing BC; DB-1311 is expected to update more early verification data for other tumor types; DIBAC platform DB1419 is expected to read out clinical data for the first time. As a leading enterprise in the field of IO2.0+ADC layout, the company has explored early combination use with the PD-L1/VEGF bispecific antibody BNT327 for the 3 ADC products developed in collaboration with BioNTech, and multiple data readouts are expected in 2026.